Pulmatrix and Eos SENOLYTIX Announce Merger Agreement to Advance Novel Mitochondrial Therapies to Improve Healthspan Accessibility StatementSkip Navigation Eos SENOLYTIX Logo (PRNewsfoto/Pulmatrix, Inc.) FRAMINGHAM, Mass. and HOUSTON, March 26, 2026 /PRNewswire/ -- Pulmatrix, Inc.(Nasdaq: PULM) ("Pulmatrix") and Eos SENOLYTIX, Inc.("Eos"), a biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases, today jointly announced a definiti ...

Product Development - Pulmatrix is focused on developing novel inhaled therapeutic products for migraine and respiratory diseases using its patented iSPERSE™ technology [323]. - The current product pipeline includes PUR3100 for acute migraine, PUR1800 for acute exacerbations of COPD, and PUR1900 for ABPA in asthma and cystic fibrosis patients [332]. - PUR3100 has received FDA acceptance for its IND and is positioned for a Phase 2 clinical study, with a study initiation contingent on financing or partnership arrangements [344]. - The Phase 1 study of PUR3100 demonstrated a lower incidence of nausea (21% vs. 86%) and vomiting (0% vs. 29%) compared to IV DHE, indicating improved tolerability [345]. - PUR1800, a Narrow Spectrum Kinase Inhibitor, has completed a Phase 1b study showing good tolerability and low systemic exposure, supporting its continued development for AECOPD [349]. - PUR1800 demonstrated safety and tolerability in toxicology studies, indicating potential for chronic dosing in respiratory diseases [350]. - The Cipla Agreement allows for 2% royalties on future net sales of PUR1900 outside the United States [353]. Financial Performance - No revenues were recognized for the year ended December 31, 2025, compared to $7.8 million for the year ended December 31, 2024, a decrease of $7.8 million [363]. - Research and development expenses were less than $0.1 million for the year ended December 31, 2025, down from $7.2 million in 2024, a decrease of approximately $7.1 million [364]. - General and administrative expenses were $5.1 million for the year ended December 31, 2025, compared to $7.8 million in 2024, a decrease of approximately $2.7 million [365]. - The accumulated deficit reached $302.3 million as of December 31, 2025, primarily due to research and development and administrative expenses [367]. - Total cash and cash equivalents as of December 31, 2025, were $4.1 million, expected to fund operations for at least the next 12 months [369]. - Net cash used in operating activities for the year ended December 31, 2025, was $5.4 million, resulting from a net loss of $5.2 million [371]. Strategic Decisions - The merger with Cullgen Inc. is subject to customary closing conditions, including regulatory approvals, and is expected to enhance Pulmatrix's business operations [326]. - The company has paused the development of its product candidates pending the outcome of the merger and is exploring monetization opportunities for its clinical assets [333]. - The strategic review process may lead to a dissolution and liquidation of the company if the merger is not consummated [330]. - The company anticipates incurring significant expenses related to pursuing strategic alternatives, including the Merger [368]. Industry Risks - The Company faces significant risks and uncertainties related to the biopharmaceutical industry, including the need for substantial additional capital for research and development efforts if product candidates are resumed [378]. - Completion of preclinical studies and clinical trials, as well as obtaining regulatory approvals, are critical steps that require extensive resources and compliance capabilities [378]. - The timeline for realizing revenue from product sales remains uncertain, even if product development efforts are successful [378]. - Recent changes in U.S. policy may adversely affect the Company's business, impacting areas such as the economy, tariffs, and healthcare [378].

Financial Performance - Revenues for the year ended December 31, 2025, decreased to nil, compared to $7.8 million for the year ended December 31, 2024[12]. - The net loss for the year ended December 31, 2025, was $5.2 million, compared to a net loss of $9.6 million for the year ended December 31, 2024[19]. Expenses - Research and development expenses decreased approximately $7.1 million to less than $0.1 million for the year ended December 31, 2025, compared to $7.2 million for the year ended December 31, 2024[13]. - General and administrative expenses decreased approximately $2.7 million to $5.1 million for the year ended December 31, 2025, compared to $7.8 million for the year ended December 31, 2024[14]. Cash Position - The total cash and cash equivalents balance as of December 31, 2025, was $4.1 million, down from $9.5 million for the year ended December 31, 2024[15]. - Pulmatrix anticipates its cash position is sufficient to fund operations into the first quarter of 2027 based on current operational efficiencies[15]. Patent Portfolio - Pulmatrix's patent portfolio related to iSPERSE™ included approximately 149 granted patents and 48 pending patent applications as of December 31, 2025[7]. Clinical Developments - PUR3100, a Phase 2-ready asset for acute migraine, received FDA acceptance of an IND application and a "study may proceed" letter[11]. - PUR1900 is approved to proceed to a Phase 3 trial in India, with Pulmatrix set to receive 2% royalties on future net sales outside the U.S.[11]. Merger Activities - The proposed merger with Cullgen is ongoing, with both companies waiving the "No Solicitation" clause to explore beneficial transactions[2].

Core Viewpoint - Pulmatrix, Inc. is focusing on advancing its proposed merger with Cullgen while also seeking to license or monetize its iSPERSE™ technology and related clinical programs, particularly in the context of its financial results for the year-end and fourth quarter of 2025 [1][2]. Financial Performance - Revenues for the year ended December 31, 2025, decreased to $0 from $7.8 million in 2024, primarily due to the wind down of the PUR1900 program [2]. - Research and development expenses dropped to less than $0.1 million in 2025 from $7.2 million in 2024, attributed to the cessation of the PUR1900 Phase 2b clinical trial and related operational reductions [2]. - General and administrative expenses decreased to $5.1 million in 2025 from $7.8 million in 2024, reflecting lower employment and operational costs [2]. - The total cash and cash equivalents as of December 31, 2025, were $4.1 million, down from $9.5 million in 2024, with expectations to fund operations into the first quarter of 2027 [2]. Proposed Merger with Cullgen - Pulmatrix entered into a merger agreement with Cullgen on November 13, 2024, with subsequent amendments, and is currently awaiting approval from the China Securities Regulatory Commission (CSRC) [1]. - The merger agreement includes a waiver of the "No Solicitation" clause, allowing both companies to explore alternative transactions while pursuing merger approval [1][2]. iSPERSE™ Technology and Clinical Programs - Pulmatrix's iSPERSE™ technology includes approximately 149 granted patents and 48 pending applications, aimed at improving drug delivery for respiratory diseases [1]. - The company is advancing its clinical programs, including PUR3100, which is ready for Phase 2 trials for acute migraine treatment, and PUR1800, which is being developed for chronic obstructive pulmonary disease [1][2]. - PUR1900, an inhaled formulation of itraconazole, is in Phase 3 trials in India, with Pulmatrix receiving 2% royalties on future net sales outside the U.S. [1][2].

Core Viewpoint - Pulmatrix and Cullgen have agreed to waive the "No Solicitation" clause in their Merger Agreement to explore alternative transactions while seeking approval from the China Securities Regulatory Commission (CSRC) for their merger [1][2]. Merger Agreement Details - The Merger Agreement between Pulmatrix and Cullgen was signed on November 13, 2024, and amended on April 7, 2025 [3]. - The Form S-4 filing related to the merger was declared effective in May 2025, and stockholders approved the merger in June 2025 [2][4][5]. - The closing of the merger is contingent upon Nasdaq's approval and CSRC's approval [5]. Financial Position - As of September 30, 2025, Pulmatrix had a total cash and cash equivalents balance of $4.8 million, which is expected to fund operations into at least the fourth quarter of 2026 [6]. Clinical Assets and Technology - Pulmatrix's proprietary iSPERSE™ technology is designed for inhaled therapeutic products aimed at treating migraine and respiratory diseases [13]. - The company has a pipeline that includes PUR3100, a Phase 2-ready asset for acute migraine treatment, and PUR1800, a Narrow Spectrum Kinase Inhibitor for chronic obstructive pulmonary disease [8][16]. - Pulmatrix's patent portfolio related to iSPERSE™ includes approximately 146 granted patents and about 50 pending applications [9]. Collaboration and Future Development - Pulmatrix is collaborating with Cipla on the development of PUR1900, an inhaled formulation of itraconazole, which is undergoing clinical trials in India [16].

Product Development - The company is focused on developing novel inhaled therapeutic products for migraine and respiratory diseases using its patented iSPERSE™ technology[68]. - The current pipeline includes PUR3100 for acute migraine, PUR1800 for acute exacerbations of COPD, and PUR1900 for ABPA in asthma and cystic fibrosis patients[77]. - PUR3100 aims to be the first orally inhaled DHE treatment for acute migraine, providing rapid relief and a favorable tolerability profile[86]. - PUR1800 demonstrated low and consistent systemic exposure with no observed safety signals, supporting its continued development for acute exacerbations in COPD[99]. - The Phase 1b study of PUR1800 was presented at the American Academy of Allergy, Asthma and Immunology conference in early 2023, indicating progress in its development[97]. - PUR3100 completed three 14-day GLP toxicology studies to support single-dose clinical studies, with plans for a chronic toxicology study to support long-term dosing[87]. - The FDA accepted the PUR3100 IND and issued a "study may proceed" letter for a Phase 2 clinical study to evaluate the safety, tolerability, and efficacy of PUR3100 in treating migraines[92]. Financial Performance - Revenues for the three months ended September 30, 2025, were $0, a decrease of $0.4 million from $0.4 million for the same period in 2024, primarily due to the completion of the PUR1900 Phase 2b clinical trial wind down[113]. - Revenues for the nine months ended September 30, 2025, were $0, a decrease of $7.8 million compared to $7.8 million for the same period in 2024[117]. - The total operating expenses for the nine months ended September 30, 2025, were $4.3 million, down $11.4 million from $15.6 million in 2024[116]. - The net loss for the nine months ended September 30, 2025, was $4.2 million, an improvement of $3.3 million compared to a net loss of $7.6 million in 2024[116]. - The accumulated deficit as of September 30, 2025, was $301.4 million, primarily due to research and development and general administrative expenses[120]. Operating Expenses - Research and development expenses were less than $0.1 million for the three months ended September 30, 2025, compared to $0.8 million for the same period in 2024, a decrease of approximately $0.8 million[114]. - General and administrative expenses were $0.9 million for the three months ended September 30, 2025, down from $2.2 million for the same period in 2024, a decrease of approximately $1.4 million[115]. - Research and development expenses were less than $0.1 million for the nine months ended September 30, 2025, down approximately $7.1 million from $7.2 million in 2024[118]. - General and administrative expenses decreased to $4.2 million for the nine months ended September 30, 2025, from $5.8 million in 2024, a reduction of approximately $1.6 million[119]. Funding and Capital Needs - The company is exploring opportunities to monetize its clinical assets and has paused the development of product candidates pending additional funding[78]. - The company anticipates needing additional funding to continue the development of existing programs and new opportunities identified for iSPERSE technology[110]. - The company anticipates needing additional capital to fund operations and may raise funds through equity offerings, debt financings, and collaborations[121]. - Cash and cash equivalents as of September 30, 2025, totaled $4.8 million, expected to fund corporate operating expenses for at least the next 12 months[122]. - Net cash used in operating activities for the nine months ended September 30, 2025, was $4.7 million, compared to $9.5 million in 2024[125][126]. - No cash was used in investing activities for the nine months ended September 30, 2025, while $0.4 million was used in 2024 for property and equipment purchases[127]. Strategic Initiatives - The merger with Cullgen is subject to customary closing conditions, including regulatory approvals, and has been extended to October 12, 2025[73]. - The strategic review process may lead to a dissolution and liquidation of the company if the merger is not consummated[75]. - The company plans to seek partnerships and license agreements to support the development and commercialization of its product candidates[84]. - The company expects to utilize external resources for further development following the MannKind Transaction, which resulted in the termination of the majority of its research and development employees[109].

Group 1 - The article does not provide any specific content or key points related to a company or industry [1]

[Corporate Overview and Strategic Initiatives](index=1&type=section&id=Corporate%20Overview%20and%20Strategic%20Initiatives) This section outlines Pulmatrix's Q3 2025 updates, the proposed Cullgen merger, and the iSPERSE™ divestment [Third Quarter 2025 Highlights & Corporate Update](index=1&type=section&id=Third%20Quarter%202025%20Highlights%20%26%20Corporate%20Update) Pulmatrix announced its third quarter 2025 financial results and a strategic plan to divest its migraine and inhalation assets, including the iSPERSE™ technology, as it focuses on completing a proposed merger with Cullgen - Pulmatrix announced third quarter 2025 financial results and a plan to divest its proprietary dry powder delivery technology, **iSPERSE™**, and related assets[1](index=1&type=chunk) - The company's focus in Q3 2025 was to advance steps to complete the proposed merger with Cullgen, a clinical-stage biopharmaceutical company focused on targeted protein degrader therapies[2](index=2&type=chunk) - If consummated, the merger would create a Nasdaq-listed company focused on targeted protein degradation technology with **three degrader programs in Phase 1 clinical trials**[2](index=2&type=chunk) [Proposed Merger with Cullgen](index=1&type=section&id=Proposed%20Merger%20with%20Cullgen) Pulmatrix entered into a merger agreement with Cullgen Inc. on November 13, 2024, which was approved by Pulmatrix stockholders on June 16, 2025. The closing is subject to customary conditions, including Nasdaq and China Security Regulatory Commission approvals, and will result in Cullgen's business continuing as the combined company - Pulmatrix entered into a merger agreement with Cullgen Inc. on **November 13, 2024**, amended on **April 7, 2025**[3](index=3&type=chunk) - Pulmatrix stockholders approved the Merger and related proposals on **June 16, 2025**[5](index=5&type=chunk) - The closing of the merger is subject to customary conditions, including Nasdaq listing approval and approval from the China Security Regulatory Commission[5](index=5&type=chunk) - If the merger is completed, Cullgen's business will continue as the business of the combined company[6](index=6&type=chunk) [Divestment Plan for iSPERSE™ Technology and Clinical Assets](index=2&type=section&id=Pulmatrix%20Currently%20Seeking%20Divestment%20of%20Clinical%20Assets%20and%20Proprietary%20iSPERSE%E2%84%A2%20Technology) As part of the proposed merger, Pulmatrix is actively seeking to divest its patent portfolio encompassing the iSPERSE™ technology and three related clinical programs, including its Phase 2-ready acute migraine program - Pulmatrix is in the process of potentially divesting its patent portfolio for **iSPERSE™ technology** and **three related clinical programs**, including its **Phase 2-ready acute migraine program**[2](index=2&type=chunk) - The company is currently seeking divestment of its clinical assets and proprietary **iSPERSE™ technology**[7](index=7&type=chunk) [iSPERSE™ Technology and Clinical Pipeline](index=2&type=section&id=iSPERSE%E2%84%A2%20Technology%20and%20Clinical%20Pipeline) This section details Pulmatrix's proprietary iSPERSE™ dry powder delivery technology and its clinical pipeline [iSPERSE™ Technology Overview](index=2&type=section&id=iSPERSE%E2%84%A2%20Technology%20Overview) iSPERSE™ is Pulmatrix's proprietary dry powder delivery technology, engineered for superior drug delivery to the lungs with small, dense, and dispersible particles, aiming to improve pharmacokinetics and reduce systemic side effects. The technology is protected by a substantial patent portfolio - **iSPERSE™** particles are engineered for superior drug delivery to the lungs, exceeding traditional dry powder performance with dispersibility advantages[10](index=10&type=chunk) - As of **September 30, 2025**, Pulmatrix's patent portfolio related to **iSPERSE™** included approximately **146 granted patents (18 U.S.)** and **50 pending patent applications**[10](index=10&type=chunk) - **iSPERSE™** is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for highly efficient drug delivery and deep penetration into the lungs[20](index=20&type=chunk) [Clinical Asset Details](index=2&type=section&id=Clinical%20Asset%20Details) Pulmatrix's clinical pipeline includes PUR3100 for acute migraine (Phase 2-ready), PUR1800 for AECOPD (Phase 1b completed), and PUR1900 for antifungal indications, which is in Phase 3 development in India through a partnership with Cipla [PUR3100 (Acute Migraine)](index=2&type=section&id=PUR3100) PUR3100, an orally inhaled DHE using iSPERSE™ technology, is a Phase 2-ready asset for acute migraine. Phase 1 results showed peak exposures in the targeted therapeutic range, rapid time to maximum concentration, and a lower incidence of nausea compared to IV DHE - **PUR3100** is an orally inhaled dihydroergotamine (DHE) engineered with **iSPERSE™ technology** for acute migraine, and is a **Phase 2-ready asset** with FDA IND acceptance[10](index=10&type=chunk) - Phase 1 trial results for **PUR3100** showed peak exposures in the targeted therapeutic range, time to maximum concentration at **five minutes**, and a lower incidence of nausea with no vomiting compared to IV DHE[10](index=10&type=chunk) [PUR1800 (AECOPD)](index=2&type=section&id=PUR1800) PUR1800, a Narrow Spectrum Kinase Inhibitor (NSKI) utilizing iSPERSE™ technology, is being developed for acute exacerbations in chronic obstructive pulmonary disease (AECOPD). A Phase 1b study in 2023 indicated PUR1800 was well-tolerated with no observed safety signals, supporting its continued development - **PUR1800** is a Narrow Spectrum Kinase Inhibitor (NSKI) engineered with **iSPERSE™ technology** for the treatment of acute exacerbations in chronic obstructive pulmonary disease (AECOPD)[10](index=10&type=chunk) - Complete results from a **Phase 1b study in 2023** indicated **PUR1800** was well-tolerated with no observed safety signals, supporting its continued development[10](index=10&type=chunk) [PUR1900 (Antifungal)](index=2&type=section&id=PUR1900) PUR1900 is an inhaled iSPERSE™ formulation of itraconazole. While Pulmatrix wound down its Phase 2b trial in 2024, its partner Cipla has completed a Phase 2 study in India and received approval to proceed with a Phase 3 clinical trial, with Pulmatrix eligible for 2% royalties on future net sales outside the United States - **PUR1900** is an inhaled **iSPERSE™ formulation** of the antifungal drug itraconazole[10](index=10&type=chunk) - Cipla, Pulmatrix's partner, completed its **Phase 2 study in India in 2025** and received approval to proceed with a **Phase 3 clinical trial**[10](index=10&type=chunk) - Pulmatrix will receive **2% royalties** on any potential future net sales by Cipla outside the United States[10](index=10&type=chunk) [Third Quarter 2025 Financial Performance](index=3&type=section&id=Third%20Quarter%202025%20Financial%20Performance) This section summarizes Pulmatrix's Q3 2025 financial results, including balance sheets and statements of operations [Overview of Financial Performance](index=3&type=section&id=Overview%20of%20Financial%20Performance) Pulmatrix reported a significant decrease in revenues, R&D expenses, and G&A expenses for Q3 2025 compared to Q3 2024, primarily due to the wind-down of the PUR1900 Phase 2b clinical trial and operational efficiencies. The company maintains a cash position sufficient to fund operations into Q4 2026 | Metric | Q3 2025 (in thousands) | Q3 2024 (in thousands) | Change (in thousands) | Change (%) | | :-------------------------- | :--------------------- | :--------------------- | :-------------------- | :--------- | | Revenues | $0 | $366 | $(366) | -100% | | Research and development | $8 | $814 | $(806) | -99.0% | | General and administrative | $858 | $2,209 | $(1,351) | -61.2% | - The decrease in revenues, R&D, and G&A expenses was primarily related to the completion of the **PUR1900 Phase 2b clinical trial wind-down**, disposal of lab/facilities lease, and employee terminations[11](index=11&type=chunk)[12](index=12&type=chunk)[13](index=13&type=chunk) | Metric | September 30, 2025 (in millions) | | :---------------------- | :------------------------------- | | Cash and cash equivalents | $4.8 | - The company anticipates its cash position is sufficient to fund operations into the **fourth quarter of 2026**[14](index=14&type=chunk) [Consolidated Balance Sheets](index=4&type=section&id=Consolidated%20Balance%20Sheets) As of September 30, 2025, Pulmatrix reported a decrease in cash and cash equivalents, total current assets, and total assets compared to December 31, 2024. Total liabilities also decreased significantly, leading to a reduction in total stockholders' equity | Metric (in thousands) | Sep 30, 2025 | Dec 31, 2024 | | :---------------------------- | :----------- | :----------- | | Cash and cash equivalents | $4,794 | $9,521 | | Total current assets | $4,972 | $9,920 | | Total assets | $4,982 | $9,943 | | Total current liabilities | $249 | $929 | | Total liabilities | $249 | $996 | | Total stockholders' equity | $4,733 | $8,947 | [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) For the three months ended September 30, 2025, Pulmatrix reported no revenues, a net loss of $0.877 million, and a net loss per share of $0.24. This represents a significant reduction in net loss compared to the same period in 2024, driven by decreased operating expenses | Metric (in thousands) | Three Months Ended Sep 30, 2025 | Three Months Ended Sep 30, 2024 | Nine Months Ended Sep 30, 2025 | Nine Months Ended Sep 30, 2024 | | :-------------------------------------------------- | :------------------------------ | :------------------------------ | :----------------------------- | :----------------------------- | | Revenues | $ - | $ 366 | $ - | $ 7,803 | | Research and development | $ 8 | $ 814 | $ 41 | $ 7,160 | | General and administrative | $ 858 | $ 2,209 | $ 4,220 | $ 5,836 | | Loss from operations | $ (866) | $ (2,657) | $ (4,261) | $ (7,811) | | Net loss | $ (877) | $ (2,587) | $ (4,234) | $ (7,573) | | Net loss per share (basic and diluted) | $ (0.24) | $ (0.71) | $ (1.16) | $ (2.07) | [Additional Company Information](index=6&type=section&id=Additional%20Company%20Information) This section provides company background, a forward-looking statements disclaimer, and investor contact information [About Pulmatrix, Inc.](index=6&type=section&id=About%20Pulmatrix%2C%20Inc.) Pulmatrix is a biopharmaceutical company focused on developing novel inhaled therapeutic products for migraine and respiratory diseases using its patented iSPERSE™ technology, which aims to improve drug delivery and patient outcomes - Pulmatrix is a biopharmaceutical company focused on developing novel inhaled therapeutic products for migraine and respiratory diseases using its patented **iSPERSE™ technology**[19](index=19&type=chunk) - The company's proprietary product pipeline includes treatments for CNS disorders (e.g., acute migraine) and serious lung diseases (e.g., COPD, ABPA)[19](index=19&type=chunk) - **iSPERSE™** is an engineered dry powder delivery platform designed to improve therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects[19](index=19&type=chunk) [Forward-Looking Statements](index=6&type=section&id=Forward-Looking%20Statements) This section provides a disclaimer regarding forward-looking statements, highlighting that actual results may differ materially due to various factors, including the consummation of the Cullgen merger, the ability to divest assets, clinical trial delays, regulatory approvals, funding, and patent protection - Forward-looking statements are subject to risks and uncertainties, and actual results could differ materially[22](index=22&type=chunk) - Key factors include the consummation and timing of the proposed merger with Cullgen, the ability to divest clinical assets, maintaining Nasdaq listing, raising capital, delays in clinical trials, and obtaining regulatory approvals[22](index=22&type=chunk) - The company disclaims any intention or obligation to revise forward-looking statements, except as required by law[22](index=22&type=chunk) [Investor Contact](index=6&type=section&id=Investor%20Contact) Contact information for investor relations is provided for inquiries - Investor contact information is provided for **Chuck Padala of LifeSci Advisors**[23](index=23&type=chunk)

Core Viewpoint - Pulmatrix, Inc. is advancing a proposed merger with Cullgen, which focuses on targeted protein degradation therapies, while also planning to divest its proprietary iSPERSE™ technology and related clinical programs [1][2][5]. Merger Details - The merger agreement with Cullgen was initially reported on November 13, 2024, and has undergone amendments [3][4]. - The merger aims to create a Nasdaq-listed company with a focus on targeted protein degradation technology, including three degrader programs in Phase 1 clinical trials [2][5]. Financial Performance - For Q3 2025, Pulmatrix reported revenues of $0, a decrease of approximately $0.4 million compared to $0.4 million in Q3 2024, primarily due to the wind down of the PUR1900 Phase 2b clinical trial [12]. - Research and development expenses decreased to less than $0.1 million, down approximately $0.8 million from $0.8 million in Q3 2024, attributed to the winding down of clinical trials and operational reductions [13]. - General and administrative expenses also decreased to $0.9 million, down approximately $1.4 million from $2.2 million in Q3 2024, mainly due to reduced employment and operating costs [14]. Cash Position - As of September 30, 2025, Pulmatrix had total cash and cash equivalents of $4.8 million, which is expected to fund operations into Q4 2026 based on current spending priorities [15]. Product Pipeline - Pulmatrix's proprietary iSPERSE™ technology is designed for the delivery of inhaled therapeutic products targeting migraine and respiratory diseases [17][18]. - The company has a pipeline that includes PUR3100, a Phase 2-ready treatment for acute migraine, and PUR1800, a treatment for chronic obstructive pulmonary disease (COPD) [7][17]. Patent Portfolio - As of September 30, 2025, Pulmatrix's patent portfolio related to iSPERSE™ includes approximately 146 granted patents and about 50 pending applications [8].

Core Insights - Pulmatrix reported zero revenue for Q2 2025, with a net loss per share of $(0.42), significantly improved from $(1.59) in Q2 2024, primarily due to reduced research and development spending [1][2][7] Financial Performance - Revenue for Q2 2025 was $0, down 100% from $1.6 million in Q2 2024 [2] - Net loss narrowed to $(1.55) million from $(5.81) million in Q2 2024, reflecting a substantial decrease in R&D expenses [7] - Research and development expenses plummeted by 99.5%, from $2.8 million in Q2 2024 to $14,000 in Q2 2025 [2][6] - General and administrative expenses decreased by 25% from $2.0 million in Q2 2024 to $1.5 million in Q2 2025 [2] - Cash and cash equivalents at the end of the period were $5.8 million, down 38.9% from $9.5 million at the end of 2024 [2][7] Strategic Focus - The company has shifted its strategic priorities, winding down its clinical business and focusing on completing its merger with Cullgen [1][4] - Pulmatrix is attempting to divest its iSPERSE™ intellectual property and related clinical programs, including PUR3100, PUR1800, and PUR1900 [8][9] - The ongoing viability of the company is contingent on the successful completion of the merger with Cullgen and monetizing its remaining assets [4][11] Operational Changes - The operational downsizing led to the completion of the PUR1900 clinical trial, resulting in the loss of former sources of operating income [5] - The company has halted most clinical operations and terminated related staff, focusing on cost containment [6][12] Future Outlook - Pulmatrix did not provide any financial guidance or operational outlook for the upcoming quarters [12] - The company’s near-term objective is to finalize the merger with Cullgen and monetize or transfer its remaining assets [12][13]